2025
Elevated serum leucine levels are associated with cognitive impairment and reduced gray matter and cerebral volume across the Alzheimer’s disease continuum
Nasiri H, Azargoonjahromi A, Nouri Z, Azimi S, Zand H, Shourideh A, Heydari S, Mahmoudvand B, Barabadi S, Samadpour N, Mohamadhosseini A, Khodadadi A, Shakeri S, Mayeli M, Initiative F. Elevated serum leucine levels are associated with cognitive impairment and reduced gray matter and cerebral volume across the Alzheimer’s disease continuum. Neuroscience 2025, 577: 47-53. PMID: 40348165, DOI: 10.1016/j.neuroscience.2025.05.013.Peer-Reviewed Original ResearchConceptsCognitive performanceBrain volumeMediation analysisAlzheimer's Disease Assessment Scale-cognitive subscaleReduced gray matterGray matter volumeStructural brain volumesAssociated with cognitive impairmentAlzheimer's diseaseGray matterMagnetic resonance imagingPoor cognitive outcomesAlzheimer's disease continuumMatter volumeT1-weighted magnetic resonance imagingBrain structuresCognitive outcomesCerebral volumeCognitive impairmentCognitive declineBrain atrophyAD continuumBrainSerum leucine levelsAD pathology
2019
Effect of AZD0530 on Cerebral Metabolic Decline in Alzheimer Disease
van Dyck CH, Nygaard HB, Chen K, Donohue MC, Raman R, Rissman RA, Brewer JB, Koeppe RA, Chow TW, Rafii MS, Gessert D, Choi J, Turner RS, Kaye JA, Gale SA, Reiman EM, Aisen PS, Strittmatter SM. Effect of AZD0530 on Cerebral Metabolic Decline in Alzheimer Disease. JAMA Neurology 2019, 76: 1219-1229. PMID: 31329216, PMCID: PMC6646979, DOI: 10.1001/jamaneurol.2019.2050.Peer-Reviewed Original ResearchAZD0530 treatmentAdverse eventsPrimary outcomeTreatment groupsAlzheimer's Disease Cooperative Study-ActivitiesAlzheimer's diseasePositron emission tomography evidenceMini-Mental State Examination scoreAlzheimer's Disease Assessment Scale-cognitive subscaleCerebral metabolic declineFrequent adverse eventsSecondary end pointsCerebral metabolic rateMild Alzheimer's dementiaState Examination scorePlasma drug levelsClinical Dementia RatingVolumetric magnetic resonanceEffect of AZD0530Neuronal cell surfaceModified intentionTreat populationSecondary outcomesNeuropsychiatric InventoryEfficacy analysis
2011
Suitability of the Clinical Dementia Rating‐Sum of Boxes as a single primary endpoint for Alzheimer's disease trials
Coley N, Andrieu S, Jaros M, Weiner M, Cedarbaum J, Vellas B. Suitability of the Clinical Dementia Rating‐Sum of Boxes as a single primary endpoint for Alzheimer's disease trials. Alzheimer's & Dementia 2011, 7: 602-610.e2. PMID: 21745761, DOI: 10.1016/j.jalz.2011.01.005.Peer-Reviewed Original ResearchConceptsClinical Dementia Rating SumCo-primary endpointsPrimary endpointSingle primary endpointCDR-SBInternal responsivenessFunctional impairmentADAS-CogDisease trialsExternal responsivenessAlzheimer's diseaseAlzheimer's Disease Assessment Scale-cognitive subscaleFloor/ceiling effectsCDR-SB changeDisease-modifying trialsModerate AD patientsDaily Living ScaleAlzheimer's disease trialsConvergent validityInternal consistencyAD trialsDisease stageAD patientsInstrumental activitiesMean change
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply